A universal fluorescence polarization high throughput screening assay to target the SAM-binding sites of SARS-CoV-2 and other viral methyltransferases

References

• de Wit E, Feldmann F, Cronin J, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6771–6776.
   PubMed Web of Science ®Google Scholar
• Owen DR, Allerton CMN, Anderson AS, et al. An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19. Science. 2021 Dec 24;374(6575):1586–1593.
   PubMed Web of Science ®Google Scholar
• Wahl A, Gralinski LE, Johnson CE, et al. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature. 2021 Mar;591(7850):451–457.
   PubMed Web of Science ®Google Scholar
• Samrat SK, Tharappel AM, Li Z, et al. Prospect of SARS-CoV-2 spike protein: potential role in vaccine and therapeutic development. Virus Res. 2020 Oct 15;288:198141.
   PubMed Web of Science ®Google Scholar
• Chan JF, Kok KH, Zhu Z, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9(1):221–236.
   PubMed Web of Science ®Google Scholar
• Romano M, Ruggiero A, Squeglia F, et al. A structural view of SARS-CoV-2 RNA replication machinery: RNA synthesis, proofreading and final capping. Cells. 2020 May 20;9(5):1267.
   PubMed Web of Science ®Google Scholar
• Bouvet M, Debarnot C, Imbert I, et al. In vitro reconstitution of SARS-coronavirus mRNA cap methylation. PLoS Pathog. 2010 Apr 22;6(4):e1000863.
   PubMed Web of Science ®Google Scholar
• Egloff MP, Benarroch D, Selisko B, et al. An RNA cap (nucleoside-2'-O-)-methyltransferase in the flavivirus RNA polymerase NS5: crystal structure and functional characterization. EMBO J. 2002;21(11):2757–2768.
   PubMed Web of Science ®Google Scholar
• Ray D, Shah A, Tilgner M, et al. West Nile virus 5'-cap structure is formed by sequential guanine N-7 and ribose 2'-O methylations by nonstructural protein 5. J Virol. 2006;80(17):8362–8370.
   PubMed Web of Science ®Google Scholar
• Dong H, Ren S, Zhang B, et al. West Nile virus methyltransferase catalyzes two methylations of the viral RNA cap through a substrate-repositioning mechanism. J Virol. 2008 May;82(9):4295–4307.
   PubMed Web of Science ®Google Scholar
• Dong H, Ray D, Ren S, et al. Distinct RNA elements confer specificity to flavivirus RNA cap methylation events. J Virol. 2007 May;81(9):4412–4421.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Ray D, Zhao Y, et al. Structure and function of flavivirus NS5 methyltransferase. J Virol. 2007 Apr;81(8):3891–3903.
   PubMed Web of Science ®Google Scholar
• Schwer B, Hausmann S, Schneider S, et al. Poxvirus mRNA cap methyltransferase. bypass of the requirement for the stimulatory subunit by mutations in the catalytic subunit and evidence for intersubunit allostery. J Biol Chem. 2006 Jul 14;281(28):18953–18960.
   PubMed Web of Science ®Google Scholar
• Bujnicki JM, Rychlewski L. Reassignment of specificities of two cap methyltransferase domains in the reovirus lambda 2 protein. Genome Biol. 2001;2(9). RESEARCH0038.
   PubMed Web of Science ®Google Scholar
• Heilmann E, Kimpel J, Geley S, et al. The methyltransferase region of vesicular stomatitis virus L polymerase is a target site for functional intramolecular insertion. Viruses. 2019 Oct 26;11(11):989.
   PubMed Web of Science ®Google Scholar
• Furuichi Y, Shatkin AJ. Viral and cellular mRNA capping: past and prospects. Adv Virus Res. 2000;55:135–184.
   PubMed Web of Science ®Google Scholar
• Park GJ, Osinski A, Hernandez G, et al. The mechanism of RNA capping by SARS-CoV-2. Nature. 2022 Sep;609(7928):793–800.
   PubMed Web of Science ®Google Scholar
• Chen Y, Cai H, Pan J, et al. Functional screen reveals SARS coronavirus nonstructural protein nsp14 as a novel cap N7 methyltransferase. Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3484–3489.
   PubMed Web of Science ®Google Scholar
• Chen Y, Guo D. Molecular mechanisms of coronavirus RNA capping and methylation. Virol Sin. 2016 Feb;31(1):3–11.
   PubMed Web of Science ®Google Scholar
• Yan L, Yang Y, Li M, et al. Coupling of N7-methyltransferase and 3'-5’ exoribonuclease with SARS-CoV-2 polymerase reveals mechanisms for capping and proofreading. Cell. 2021 Jun 24;184(13):3474–3485e11.
   PubMed Web of Science ®Google Scholar
• Decroly E, Imbert I, Coutard B, et al. Coronavirus nonstructural protein 16 is a cap-0 binding enzyme possessing (nucleoside-2'O)-methyltransferase activity [Research Support, Non-U.S. Gov't]. Journal of Virology. 2008 Aug;82(16):8071–8084.
   PubMed Web of Science ®Google Scholar
• Bouvet M, Lugari A, Posthuma CC, et al. Coronavirus Nsp10, a critical co-factor for activation of multiple replicative enzymes. J Biol Chem. 2014 Sep 12;289(37):25783–25796.
   PubMed Web of Science ®Google Scholar
• Minskaia E, Hertzig T, Gorbalenya AE, et al. Discovery of an RNA virus 3'->5’ exoribonuclease that is critically involved in coronavirus RNA synthesis. Proc Natl Acad Sci U S A. 2006 Mar 28;103(13):5108–5113.
   PubMed Web of Science ®Google Scholar
• von Grotthuss M, Wyrwicz LS, Rychlewski L. mRNA cap-1 methyltransferase in the SARS genome. Cell. 2003 Jun 13;113(6):701–702.
   PubMed Web of Science ®Google Scholar
• Bouvet M, Imbert I, Subissi L, et al. RNA 3'-end mismatch excision by the severe acute respiratory syndrome coronavirus nonstructural protein nsp10/nsp14 exoribonuclease complex. Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9372–9377.
   PubMed Web of Science ®Google Scholar
• Saramago M, Barria C, Costa VG, et al. New targets for drug design: importance of nsp14/nsp10 complex formation for the 3'-5’ exoribonucleolytic activity on SARS-CoV-2. FEBS J. 2021 Sep;288(17):5130–5147.
   PubMed Web of Science ®Google Scholar
• Decroly E, Debarnot C, Ferron F, et al. Crystal structure and functional analysis of the SARS-coronavirus RNA cap 2'-O-methyltransferase nsp10/nsp16 complex. PLoS Pathog. 2011 May;7(5):e1002059.
   PubMed Web of Science ®Google Scholar
• Lugari A, Betzi S, Decroly E, et al. Molecular mapping of the RNA Cap 2'-O-methyltransferase activation interface between severe acute respiratory syndrome coronavirus nsp10 and nsp16. J Biol Chem. 2010 Oct 22;285(43):33230–33241.
   PubMed Web of Science ®Google Scholar
• Ogando NS, El Kazzi P, Zevenhoven-Dobbe JC, et al. Structure-function analysis of the nsp14 N7-guanine methyltransferase reveals an essential role in Betacoronavirus replication. Proc Natl Acad Sci U S A. 2021 Dec 7;118(49):e2108709118.
   PubMed Web of Science ®Google Scholar
• Chen Y, Tao J, Sun Y, et al. Structure-function analysis of severe acute respiratory syndrome coronavirus RNA cap guanine-N7-methyltransferase. J Virol. 2013 Jun;87(11):6296–6305.
   PubMed Web of Science ®Google Scholar
• Copeland RA, Solomon ME, Richon VM. Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724–732.
   PubMed Web of Science ®Google Scholar
• Liu L, Dong H, Chen H, et al. Flavivirus RNA cap methyltransferase: structure, function, and inhibition. Front Biol. 2010 Aug 1;5(4):286–303.
   Google Scholar
• Aouadi W, Eydoux C, Coutard B, et al. Toward the identification of viral cap-methyltransferase inhibitors by fluorescence screening assay. Antiviral Res. 2017 Aug;144:330–339.
   PubMed Web of Science ®Google Scholar
• Otava T, Sala M, Li F, et al. The structure-based design of SARS-CoV-2 nsp14 methyltransferase ligands yields nanomolar inhibitors. ACS Infect Dis. 2021 Aug 13;7(8):2214–2220.
   PubMed Web of Science ®Google Scholar
• Pearson LA, Green CJ, Lin D, et al. Development of a high-throughput screening assay to identify inhibitors of the SARS-CoV-2 guanine-N7-methyltransferase using RapidFire MASS SPECTROMETRY. SLAS Discov. 2021 Jul;26(6):749–756.
   PubMed Web of Science ®Google Scholar
• Devkota K, Schapira M, Perveen S, et al. Probing the SAM binding site of SARS-CoV-2 Nsp14 in vitro using SAM competitive inhibitors guides developing selective bisubstrate inhibitors. SLAS Discov. 2021 Oct;26(9):1200–1211.
   PubMed Web of Science ®Google Scholar
• Basu S, Mak T, Ulferts R, et al. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp14 RNA cap methyltransferase. Biochem J. 2021 Jul 16;478(13):2481–2497.
   PubMedGoogle Scholar
• Ahmed-Belkacem R, Sutto-Ortiz P, Guiraud M, et al. Synthesis of adenine dinucleosides SAM analogs as specific inhibitors of SARS-CoV nsp14 RNA cap guanine-N7-methyltransferase. Eur J Med Chem. 2020 Sep 1;201:112557.
   PubMed Web of Science ®Google Scholar
• Kasprzyk R, Spiewla TJ, Smietanski M, et al. Identification and evaluation of potential SARS-CoV-2 antiviral agents targeting mRNA cap guanine N7-methyltransferase. Antiviral Res. 2021 Sep;193:105142.
   PubMed Web of Science ®Google Scholar
• Brecher M, Chen H, Li Z, et al. Identification and characterization of novel broad-spectrum inhibitors of the flavivirus methyltransferase. ACS Infect Dis. 2015;1(8):340–349.
   PubMed Web of Science ®Google Scholar
• Zeng C, Wu A, Wang Y, et al. Identification and characterization of a ribose 2'-O-methyltransferase encoded by the ronivirus branch of nidovirales. J Virol. 2016 Aug 1;90(15):6675–6685.
   PubMed Web of Science ®Google Scholar
• Sutto-Ortiz P, Tcherniuk S, Ysebaert N, et al. The methyltransferase domain of the respiratory syncytial virus L protein catalyzes cap N7 and 2'-O-methylation. PLoS Pathog. 2021 May;17(5):e1009562.
   PubMed Web of Science ®Google Scholar
• Luan Y, Blazer LL, Hu H, et al. Design of a fluorescent ligand targeting the S-adenosylmethionine binding site of the histone methyltransferase MLL1. Org Biomol Chem. 2016 Jan 14;14(2):631–638.
   PubMed Web of Science ®Google Scholar
• Moeller NH, Shi K, Demir O, et al. Structure and dynamics of SARS-CoV-2 proofreading exoribonuclease ExoN. Proc Natl Acad Sci U S A. 2022 Mar 1;119(9):e2106379119.
   PubMed Web of Science ®Google Scholar
• Lin S, Chen H, Chen Z, et al. Crystal structure of SARS-CoV-2 nsp10 bound to nsp14-ExoN domain reveals an exoribonuclease with both structural and functional integrity. Nucleic Acids Res. 2021 May 21;49(9):5382–5392.
   PubMed Web of Science ®Google Scholar
• Liu C, Shi W, Becker ST, et al. Structural basis of mismatch recognition by a SARS-CoV-2 proofreading enzyme. Science. 2021 Sep 3;373(6559):1142–1146.
   PubMed Web of Science ®Google Scholar
• Calvet G, Aguiar RS, Melo AS, et al. Detection and sequencing of Zika virus from amniotic fluid of fetuses with microcephaly in Brazil: a case study. Lancet Infect Dis. 2016 Feb 17;16:653–660.
   PubMed Web of Science ®Google Scholar
• Martines RB, Bhatnagar J, Keating MK, et al. Notes from the field: evidence of Zika virus infection in brain and placental tissues from two congenitally infected newborns and two fetal losses – Brazil, 2015. MMWR Morb Mortal Wkly Rep. 2016;65(6):159–160.
   PubMed Web of Science ®Google Scholar
• Chen H, Liu L, Jones SA, et al. Selective inhibition of the West Nile virus methyltransferase by nucleoside analogs. Antiviral Res. 2013 Mar;97(3):232–239.
   PubMed Web of Science ®Google Scholar
• Chen H, Zhou B, Brecher M, et al. S-adenosyl-homocysteine is a weakly bound inhibitor for a flaviviral methyltransferase. PLoS One. 2013;8(10):e76900.
   PubMed Web of Science ®Google Scholar
• Roingeard P, Beaumont E. Hepatitis C vaccine: 10 good reasons for continuing. Hepatology. 2020 May;71(5):1845–1850.
   PubMed Web of Science ®Google Scholar
• Montaner JS, Lima VD, Harrigan PR, et al. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the “HIV treatment as prevention” experience in a Canadian setting. PLoS One. 2014;9(2):e87872.
   PubMed Web of Science ®Google Scholar
• Moreno S, Perno CF, Mallon PW, et al. Two-drug vs. three-drug combinations for HIV-1: Do we have enough data to make the switch? HIV Med. 2019 Apr;20(Suppl 4):2–12.
   PubMedGoogle Scholar
• Ma MJ, Qiu SF, Cui XM, et al. Persistent SARS-CoV-2 infection in asymptomatic young adults. Signal Transduct Target Ther. 2022 Mar 9;7(1):77.
   PubMed Web of Science ®Google Scholar
• Avanzato VA, Matson MJ, Seifert SN, et al. Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer. Cell. 2020 Dec 23;183(7):1901–1912. e9.
   PubMed Web of Science ®Google Scholar
• Baang JH, Smith C, Mirabelli C, et al. Prolonged severe acute respiratory syndrome coronavirus 2 replication in an immunocompromised patient. J Infect Dis. 2021 Jan 4;223(1):23–27.
   PubMed Web of Science ®Google Scholar
• Choi B, Choudhary MC, Regan J, et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med. 2020 Dec 3;383(23):2291–2293.
   PubMed Web of Science ®Google Scholar
• Kemp SA, Collier DA, Datir RP, et al. SARS-CoV-2 evolution during treatment of chronic infection. Nature. 2021 Apr;592(7853):277–282.
   PubMed Web of Science ®Google Scholar
• Moran E, Cook T, Goodman AL, et al. Persistent SARS-CoV-2 infection: the urgent need for access to treatment and trials. Lancet Infect Dis. 2021 Oct;21(10):1345–1347.
   PubMed Web of Science ®Google Scholar
• Jacobs JJL. Persistent SARS-2 infections contribute to long COVID-19. Med Hypotheses. 2021 Apr;149:110538.
   PubMed Web of Science ®Google Scholar
• Truong TT, Ryutov A, Pandey U, et al. Increased viral variants in children and young adults with impaired humoral immunity and persistent SARS-CoV-2 infection: A consecutive case series. EBioMedicine. 2021 May;67:103355.
   PubMed Web of Science ®Google Scholar
• Taha Y, Wardle H, Evans AB, et al. Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy. Ann Clin Microbiol Antimicrob. 2021 Dec 30;20(1):85.
   PubMed Web of Science ®Google Scholar
• Gaspar-Rodriguez A, Padilla-Gonzalez A, Rivera-Toledo E. Coronavirus persistence in human respiratory tract and cell culture: An overview. Braz J Infect Dis. . 2021 Sep-Oct;25(5):101632.
   PubMed Web of Science ®Google Scholar
• Li Z, Tharappel AM, Xu J, et al. Small-molecule inhibitors for the Prp8 intein as antifungal agents. Proc Natl Acad Sci U S A. 2021 Jan 12;118(2):e2008815118.
   PubMed Web of Science ®Google Scholar
• Nguyenla X, Wehri E, Van Dis E, et al. Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells. Sci Rep. 2022 Nov 2;12(1):18506.
   PubMed Web of Science ®Google Scholar
• Yadav B, Wennerberg K, Aittokallio T, et al. Searching for drug synergy in complex dose-response landscapes using an interaction potency model. Comput Struct Biotechnol J. 2015;13:504–513.
   PubMed Web of Science ®Google Scholar
• Vuong W, Fischer C, Khan MB, et al. Improved SARS-CoV-2 M(pro) inhibitors based on feline antiviral drug GC376: structural enhancements, increased solubility, and micellar studies. Eur J Med Chem. 2021 Oct 15;222:113584.
   PubMed Web of Science ®Google Scholar
• Vuong W, Khan MB, Fischer C, et al. Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication. Nat Commun. 2020 Aug 27;11(1):4282.
   PubMed Web of Science ®Google Scholar
• Bai B, Belovodskiy A, Hena M, et al. Peptidomimetic alpha-acyloxymethylketone warheads with Six-membered lactam P1 glutamine mimic: SARS-CoV-2 3CL protease inhibition, coronavirus antiviral activity, and in vitro biological stability. J Med Chem. 2022 Feb 24;65(4):2905–2925.
   PubMed Web of Science ®Google Scholar
• Arutyunova E, Khan MB, Fischer C, et al. N-Terminal finger stabilizes the S1 pocket for the reversible feline drug GC376 in the SARS-CoV-2 M(pro) dimer. J Mol Biol. 2021 Jun 25;433(13):167003.
   PubMed Web of Science ®Google Scholar
• Bai B, Belovodskiy A, Hena M, et al. Peptidomimetic alpha-acyloxymethylketone warheads with six-membered lactam P1 glutamine mimic: SARS-CoV-2 3CL protease inhibition, coronavirus antiviral activity, and in vitro biological stability. J Med Chem. 2022 Feb 24;65(4):2905–2925.
   PubMed Web of Science ®Google Scholar
• Lu J, Chen SA, Khan MB, et al. Crystallization of feline coronavirus M(pro) With GC376 reveals mechanism of inhibition. Front Chem. 2022;10:852210.
   PubMed Web of Science ®Google Scholar
• Decroly E, Ferron F, Lescar J, et al. Conventional and unconventional mechanisms for capping viral mRNA. Nat Rev Microbiol. 2011 Dec 5;10(1):51–65.
   PubMed Web of Science ®Google Scholar
• Gnyszka A, Jastrzebski Z, Flis S. DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer. Anticancer Res. 2013 Aug;33(8):2989–2996.
   PubMed Web of Science ®Google Scholar
• Mullard A. FDA approves an inhibitor of a novel ‘epigenetic writer’. Nat Rev Drug Discov. 2020 Mar;19(3):156.
   Web of Science ®Google Scholar
• Ganesan A, Arimondo PB, Rots MG, et al. The timeline of epigenetic drug discovery: from reality to dreams. Clin Epigenetics. 2019 Dec 2;11(1):174.
   PubMed Web of Science ®Google Scholar
• Dong H, Liu L, Zou G, et al. Structural and functional analyses of a conserved hydrophobic pocket of flavivirus methyltransferase [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.]. The Journal of Biological Chemistry. 2010 Oct 15;285(42):32586–32595.
   PubMed Web of Science ®Google Scholar
• Lim SP, Sonntag LS, Noble C, et al. Small molecule inhibitors that selectively block dengue virus methyltransferase [research support, Non-U.S. gov't]. The Journal of Biological Chemistry. 2011 Feb 25;286(8):6233–6240.
   PubMed Web of Science ®Google Scholar
• Pan R, Kindler E, Cao L, et al. N7-Methylation of the coronavirus RNA Cap Is required for maximal virulence by preventing innate immune recognition. mBio. 2022 Feb 22;13(1):e0366221
   PubMed Web of Science ®Google Scholar
• Bobrovs R, Kanepe I, Narvaiss N, et al. Discovery of SARS-CoV-2 Nsp14 and Nsp16 methyltransferase inhibitors by high-throughput virtual screening. Pharmaceuticals (Basel). 2021 Nov 30;14(12):1243.
   PubMedGoogle Scholar
• Selvaraj C, Dinesh DC, Panwar U, et al. Structure-based virtual screening and molecular dynamics simulation of SARS-CoV-2 guanine-N7 methyltransferase (nsp14) for identifying antiviral inhibitors against COVID-19. J Biomol Struct Dyn. 2021 Aug;39(13):4582–4593.
   PubMed Web of Science ®Google Scholar
• Liu C, Zhu X, Lu Y, et al. Potential treatment with Chinese and western medicine targeting NSP14 of SARS-CoV-2. J Pharm Anal. 2021 Jun;11(3):272–277.
   PubMed Web of Science ®Google Scholar
• Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen. 1999;4(2):67–73.
   PubMed Web of Science ®Google Scholar
• Brecher M, Chen H, Liu B, et al. Novel broad spectrum inhibitors targeting the flavivirus methyltransferase. PLoS One. 2015;10(6):e0130062.
   PubMed Web of Science ®Google Scholar
• Li Z, Brecher M, Zhang J, et al. Existing drugs as broad-spectrum and potent inhibitors for Zika virus by targeting NS2B-NS3 interaction. Cell Res. 2017;27:1046–1064.
   PubMed Web of Science ®Google Scholar
• Li Z, Xu J, Lang Y, et al. JMX0207, a niclosamide derivative with improved pharmacokinetics, suppresses Zika virus infection both In vitro and In vivo. ACS Infect Dis. 2020 Oct 9;6(10):2616–2628.
   PubMed Web of Science ®Google Scholar